diaRNAgnosis is a new pan-European, multidisciplinary and cross-sectoral team aiming to develop a reliable and innovative method and platform to identify cancer biomarkers in liquid biopsies. Cell-free circulating ribonucleic acids (ccfRNAs) represent an important emerging class of molecules capable of providing significant clinical relevance as novel biomarkers for cancer screening, prognosis and therapy monitoring. By analysing specific circulating RNA sequences, mutations and concentrations in biological fluids, different types and stages of cancer can be accurately correlated. The aim of the diaRNAgnosis project is to complete the development of the ODG platform, providing reliable and robust detection of novel ccfRNA signatures that could be linked to specific cancer types. To ensure the timely delivery and success of the diaRNAgnosis project, DESTINA and OPTOI have engaged partners to add real value to the consortium. These are the Spanish company NanoGetic SL (specialised in nanotechnologies); three key academic research groups from the Universities of Trento and Catania (Italy), Granada (Spain); as well as the Princess Máxima Centre (The Netherlands).

Code: IP2-UGR

Funding entity: Comisión Europea

Competitive: Si

Center: GENYO

Time of implementation: 01/01/2021 – 01/12/2024

Principal Investigator: Dra. Rosario Sánchez

More information: https://www.diarnagnosis.com/

Other international projects